Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/05/2924503/0/en/Osteal-Therapeutics-Presents-Positive-Six-Month-Results-from-the-APEX-Clinical-Trial-Program-at-the-34th-Annual-Musculoskeletal-Infection-Society-Meeting.html
https://www.pharmaceutical-technology.com/news/osteal-raises-50m-to-bring-joint-infection-drug-device-combo-to-market/
https://www.globenewswire.com/news-release/2024/06/05/2893897/0/en/Osteal-Therapeutics-Closes-50M-Series-D-Financing-to-Support-Approval-and-Commercial-Launch-of-Lead-Candidate.html
https://www.globenewswire.com/news-release/2023/12/05/2790778/0/en/Osteal-Therapeutics-VT-X7-Receives-FDA-s-Breakthrough-Therapy-Designation-for-the-treatment-of-periprosthetic-joint-infection-of-the-hip-and-knee-and-completes-enrollment-of-the-pi.html
https://www.globenewswire.com//news-release/2023/09/28/2751084/0/en/BioNTX-Names-Osteal-Therapeutics-2023-Rising-Star.html
https://www.globenewswire.com//news-release/2023/09/21/2747256/0/en/Osteal-Therapeutics-Closes-23M-Series-C-Financing.html
https://www.globenewswire.com/news-release/2023/02/07/2603284/0/en/Osteal-Therapeutics-Announces-First-Subject-Enrollment-in-Second-Phase-2-Clinical-Trial-of-VT-X7-Combination-Product-for-Treatment-of-Periprosthetic-Joint-Infection.html
https://www.globenewswire.com/news-release/2022/12/29/2580648/0/en/Osteal-Therapeutics-Announces-Leadership-Team-Appointments.html
https://www.globenewswire.com/news-release/2022/11/04/2548710/0/en/Osteal-Therapeutics-Inc-Completes-Enrollment-in-APEX-Phase-2-Clinical-Trial-of-VT-X7-for-Periprosthetic-Joint-Infection.html
https://www.globenewswire.com/news-release/2022/03/08/2398964/0/en/Osteal-Therapeutics-Closes-an-Oversubscribed-30-Million-Series-B-Financing-to-Advance-Platform-Therapy-for-Treatment-of-Musculoskeletal-Infection.html